Press Releases Cyxone AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:46 2024-05-03 am EDT			5-day change	1st Jan Change
0.089 ^SEK	-0.45%		-4.09%	-11.35%

Apr. 22	Sweden's Cyxone Appoints New CEO	MT
Apr. 22	Cyxone AB Announces Chief Executive Officer Changes	CI

Kjell Stenberg new CEO in Cyxone AB	Apr. 22	AQ
BioStock: Cyxone comments on the clinical collaboration in the UK	Mar. 28	AQ
Cyxone enters important research collaboration	Mar. 25	AQ
BioStock: Cyxone's CEO gives a status update	Mar. 05	AQ
BioStock: Cyxone identifies target protein for rabeximod	Jan. 17	AQ
Cyxone reaches important milestone regarding mechanism of action	Jan. 15	AQ
Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor	Nov. 20	AQ
Interim Report 1 January to 30 September 2023	23-10-27	AQ
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K	23-10-09	AQ
BioStock Investor Meeting: Cyxone	23-09-27	AQ
Interim Report 1 January to 30 June 2023	23-08-30	AQ
Cyxone revises strategy for commercial alignment targeting valuable market opportunities	23-08-29	AQ
Cyxone appoints Urban Ottosson as new CFO	23-06-15	AQ
Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K	23-05-31	AQ
Cyxone : Bulletin of the Annual General Meeting	23-05-30	PU
Bulletin from the annual general meeting in Cyxone AB on 30 May 2023	23-05-30	AQ
Interim Report 1 January to 31 March 2023	23-05-12	AQ
Cyxone receives patent approval from the US for the salt forms of the compound rabeximod	23-05-09	AQ
Cyxone : Annual Report from Cyxone AB for the period 1 January 2022 to 31 December 2022	23-04-26	PU
Cyxone : Nomination Committee proposals and reasoned statement	23-04-26	PU

No results for this search